Benjamin Shapiro - 12 Nov 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
13 Nov 2026, 21:12:14 UTC
Prior SEC filing
05 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Benjamin Shapiro
Filing notes and source

Key filing fact

Benjamin Shapiro filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 13 Nov 2026.

Key facts

  • This page summarizes Benjamin Shapiro's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 13 Nov 2026, 21:12.

Change

  • Previous filing in this sequence was filed on 05 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001974846 Primary reporting owner

Shapiro Benjamin

Relationship
Director
Address
1185 AVENUE OF THE AMERICAS, NEW YORK
Signature
/s/ Benjamin Shapiro
Signature date
13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Award

Transaction value
Shares
+72,780
Change %
+59%
Price
Shares after
196,000
Date
12 Nov 2026
Ownership
Direct
Footnotes
F1
ORMP transaction

Common Stock

Award

Transaction value
Shares
+1,050
Change %
+0.54%
Price
Shares after
197,050
Date
12 Nov 2026
Ownership
Direct
Footnotes
F2
ORMP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,900,000
Date
12 Nov 2026
Ownership
By trust
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 72,780 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual Board awards for fiscal years 2027 and 2028. Of these shares, 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2027, and 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2028, in each case subject to the reporting person's continued service. No annual Board award will be granted to the reporting person for fiscal year 2028.

Footnote F2

On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 1,050 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's fiscal year 2027 committee awards, which vest in four substantially equal quarterly installments beginning April 1, 2027, subject to the reporting person's continued service.

Footnote F3

These shares of Common Stock are held by a trust of which the reporting person is a trustee and beneficiary.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .